Molecular Profile | NPM1-ALK ALK N1178H |
Therapy | Crizotinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Create By | c-seddy |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | NPM1-ALK ALK N1178H | Advanced Solid Tumor | sensitive | Crizotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034). | 25749034 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(25749034) | NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. | Full reference... |